Rohto Pharmaceutical Co Ltd
TSE:4527

Watchlist Manager
Rohto Pharmaceutical Co Ltd Logo
Rohto Pharmaceutical Co Ltd
TSE:4527
Watchlist
Price: 2 854.5 JPY -0.4%
Market Cap: 674.2B JPY
Have any thoughts about
Rohto Pharmaceutical Co Ltd?
Write Note

Rohto Pharmaceutical Co Ltd
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Rohto Pharmaceutical Co Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Rohto Pharmaceutical Co Ltd
TSE:4527
Total Current Liabilities
ÂĄ111.1B
CAGR 3-Years
14%
CAGR 5-Years
15%
CAGR 10-Years
7%
Shiseido Co Ltd
TSE:4911
Total Current Liabilities
ÂĄ411.9B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
5%
Kao Corp
TSE:4452
Total Current Liabilities
ÂĄ473.4B
CAGR 3-Years
7%
CAGR 5-Years
3%
CAGR 10-Years
4%
Kose Corp
TSE:4922
Total Current Liabilities
ÂĄ62.7B
CAGR 3-Years
3%
CAGR 5-Years
1%
CAGR 10-Years
6%
F
Fancl Corp
TSE:4921
Total Current Liabilities
ÂĄ15.6B
CAGR 3-Years
7%
CAGR 5-Years
-1%
CAGR 10-Years
7%
Kobayashi Pharmaceutical Co Ltd
TSE:4967
Total Current Liabilities
ÂĄ39.6B
CAGR 3-Years
-1%
CAGR 5-Years
-3%
CAGR 10-Years
2%
No Stocks Found

Rohto Pharmaceutical Co Ltd
Glance View

Market Cap
651.2B JPY
Industry
Consumer products

Rohto Pharmaceutical Co Ltd., a company deeply rooted in the legacy of Japanese innovation, traces its beginnings to the late 19th century. Initially specializing in over-the-counter (OTC) medicines, it has adeptly expanded its reach to include skincare and healthcare products. The company’s journey from its inception was marked by a relentless pursuit of addressing the evolving needs of its consumer base, leveraging its expertise in pharmaceuticals and chemistry to create products that cater to health and wellness. Rohto's commitment to research and development has enabled it to pioneer unique formulations, effectively blending traditional practices with modern scientific advances. This strategy has allowed Rohto to establish a strong foothold not only in Japan but also in international markets, appealing to a broad demographic. The core of Rohto's business lies in its ability to commercialize its innovative solutions across various channels. The company generates revenue primarily through the sale of its diversified product lines, which include eye drops, dermatological creams, and other personal care products. Rohto’s strategic acquisitions and partnerships have also played a critical role in its growth, enabling it to expand its market presence and adapt to global health trends. The ability to anticipate and respond to consumer needs allows Rohto to maintain a robust product pipeline, ensuring consistent sales performance. Through its global distribution networks and focused marketing efforts, Rohto capitalizes on its brand reputation for quality and reliability, ensuring a steady stream of profits.

Intrinsic Value
3 201.93 JPY
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Rohto Pharmaceutical Co Ltd's Total Current Liabilities?
Total Current Liabilities
111.1B JPY

Based on the financial report for Sep 30, 2024, Rohto Pharmaceutical Co Ltd's Total Current Liabilities amounts to 111.1B JPY.

What is Rohto Pharmaceutical Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
7%

Over the last year, the Total Current Liabilities growth was 34%. The average annual Total Current Liabilities growth rates for Rohto Pharmaceutical Co Ltd have been 14% over the past three years , 15% over the past five years , and 7% over the past ten years .

Back to Top